Daphne S. Cukierman

ALZHEIMER'S DISEASE: ETIOLOGICAL HYPOTHESES AND TREATMENT PERSPECTIVES

Anna De Falco, Daphne S. Cukierman, Rachel Ann Hauser‐Davis et al. · Química Nova · 2015 · 79 citations · Full text

Medicine, Neurology, Neuroscience +17

A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson's disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies

Daphne S. Cukierman, Ana Beatriz Pinheiro, Sergio Luiz Pinto Castiñeiras Filho et al. · Journal of Inorganic Biochemistry · 2017 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Toxicology +12

Disruption of zinc and copper interactions with Aβ(1–40) by a non-toxic, isoniazid-derived, hydrazone: a novel biometal homeostasis restoring agent in Alzheimer's disease therapy?

Rachel Ann Hauser‐Davis, Leonardo V. De Freitas, Daphne S. Cukierman et al. · Metallomics · 2015 · 44 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Aroylhydrazones constitute a promising class of ‘metal-protein attenuating compounds’ for the treatment of Alzheimer’s disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone

Daphne S. Cukierman, Elio Accardo, Rosana Garrido Gomes et al. · JBIC Journal of Biological Inorganic Chemistry · 2018 · 40 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +13

X1INH, an improved next-generation affinity-optimized hydrazonic ligand, attenuates abnormal copper(<scp>i</scp>)/copper(<scp>ii</scp>)-α-Syn interactions and affects protein aggregation in a cellular model of synucleinopathy

Daphne S. Cukierman, Diana F. Lázaro, Pamela Sacco et al. · Dalton Transactions · 2020 · 35 citations

Life Sciences, Biochemistry, Chemistry +14